The CD44 antigen (CD44), depicted in the tumor invasion network (Supplementary Figure 5) was selected for orthogonal cross-validation because of its well-described role in tumorigenesis and invasion of lung adenocarcinoma driven by oncogenic KRas mutants [41, 42]. The gene discussed is KRAS; the disease is lung adenocarcinoma.